 |
|
Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review
Lei Miao, Jing Xu, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng
Clin Mol Hepatol. 2022;28(4):725-738. Published online 2022 Mar 14 DOI: https://doi.org/10.3350/cmh.2022.0015
|
|
Citations to this article as recorded by
 Meta‐analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non‐alcoholic steatohepatitis and non‐alcoholic steatohepatitis‐related fibrosis
Rutao Lin, Jianghua Zhou, Qinmei Sun, Xin Xin, Yiyang Hu, Minghua Zheng, Qin Feng
Alimentary Pharmacology & Therapeutics.2024; 59(7): 802. CrossRef Current status and future trends of the global burden of MASLD
Lei Miao, Giovanni Targher, Christopher D. Byrne, Ying-Ying Cao, Ming-Hua Zheng
Trends in Endocrinology & Metabolism.2024;[Epub] CrossRef Optimized strategy among diet, exercise, and pharmacological interventions for nonalcoholic fatty liver disease: A network meta‐analysis of randomized controlled trials
Hao Wang, Qianqian Ma, Youpeng Chen, Ling Luo, Junzhao Ye, Bihui Zhong
Obesity Reviews.2024;[Epub] CrossRef Non-alcoholic fatty liver disease: a current challenge of interdisciplinary research
E. V. Biryukova
Meditsinskiy sovet = Medical Council.2024; (6): 72. CrossRef MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development
Farah Khaznadar, Omar Khaznadar, Ana Petrovic, Marija Hefer, Fabian Gjoni, Stefan Gjoni, Justinija Steiner, Martina Smolic, Kristina Bojanic
Current Issues in Molecular Biology.2024; 46(7): 6300. CrossRef AI‐based digital pathology provides newer insights into lifestyle intervention‐induced fibrosis regression in MASLD: An exploratory study
Hai‐Yang Yuan, Xiao‐Fei Tong, Ya‐Yun Ren, Yang‐Yang Li, Xin‐Lei Wang, Li‐Li Chen, Sui‐Dan Chen, Xiao‐Zhi Jin, Xiao‐Dong Wang, Giovanni Targher, Christopher D. Byrne, Lai Wei, Vincent W.‐S Wong, Dean Tai, Arun J. Sanyal, Hong You, Ming‐Hua Zheng
Liver International.2024;[Epub] CrossRef Association of Dipeptidyl Peptidase-4 Inhibitors Use with Reduced Risk of Hepatocellular Carcinoma in Type 2 Diabetes Patients with Chronic HBV Infection
Tzu-I Chen, Fu-Jen Lee, Wan-Lun Hsu, Yong-Chen Chen, Mingchih Chen
Cancers.2023; 15(4): 1148. CrossRef Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?
Ho Soo Chun, Minjong Lee
Clinical and Molecular Hepatology.2023; 29(2): 377. CrossRef In praise of pioglitazone: An economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome
David S. H. Bell, Terri Jerkins
Diabetes, Obesity and Metabolism.2023; 25(11): 3093. CrossRef Vitamin E and Pioglitazone: A Comprehensive Systematic Review of Their Efficacy in Non-alcoholic Fatty Liver Disease
Iqra J Mazhar, Mohamed Yasir, Saba Sarfraz, Gandhala Shlaghya, Sri Harsha Narayana, Ujala Mushtaq, Basim Shaman Ameen, Chuhao Nie, Daniel Nechi, Sai Sri Penumetcha
Cureus.2023;[Epub] CrossRef Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD)
Iryna Kostitska, Nadia Protas, Liliia Petrovska
Diabetes Obesity Metabolic Syndrome.2023; (5): 8. CrossRef Portal hypertension in nonalcoholic fatty liver disease: Challenges and perspectives
Lei Miao, Giovanni Targher, Christopher D. Byrne, Luca Valenti, Xiaolong Qi, Ming‐Hua Zheng
Portal Hypertension & Cirrhosis.2022; 1(1): 57. CrossRef The effect of metformin usage on survival outcomes for hepatocellular carcinoma patients with type 2 diabetes mellitus after curative therapy
Bo Yuan, Jichun Ma, Jing Wang, Jinyong Hao
Frontiers in Endocrinology.2022;[Epub] CrossRef
|